categorized regarding the specifics of the type of data requested. Using a comparative framework to examine the recommendations of CDR and NICE, we describe the frequency of the different types of data recommended for collection post-launch to highlight trends across jurisdictions RESULTS: Thirty-four of 64 CDR submissions recommended 'no listing', 17 'list with criteria', and 13 'list or list in similar manner as other drugs in the same category'. Of the 64 appraisals, 41 were recommended to conduct further research to either collect specific items of data (n = 28), conduct subgroup analysis (n = 13), or collect data using a more appropriate study design (n = 19). The most commonly requested item was long-term adverse events or safety data (16/28), and this observation is consistent with the fact that, to date, most post-launch studies are safety surveillance studies. In addition 11 of 28 recommended the collection of clinically important outcomes, long-term effectiveness (7/28). Similarly, 41 of 48 NICE appraisals recommended further research to collect real-world data, including treatment pathways, effectiveness, and long-term effectiveness or adverse events. CONCLUSION: This review suggests that recommendations for post-launch research from CDR and NICE appear to be similar. This highlights the inherent weakness of regulatory trials as a piece of evidence in informing reimbursement decisions. OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer acetate (GA) compared to natalizumab (NZ) in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the presence of long-term clinical evidence. METHODS: A literature-based Markov model was developed with patients transitioning through health-states based on Kurtzke expanded disability status scale (EDSS). Patients in the model are Ն21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $430,242 and for NZ were $498,728. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $208,879 and $525,463 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSIONS: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
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PHP18 HEALTH CARE DECISION-MAKERS' ATTITUDE ON HEALTH ECONOMICS RESEARCH
Galani Berardo C Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer acetate (GA) compared to natalizumab (NZ) in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) in the presence of long-term clinical evidence. METHODS: A literature-based Markov model was developed with patients transitioning through health-states based on Kurtzke expanded disability status scale (EDSS) . Patients in the model are Ն21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $430,242 and for NZ were $498,728. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $208,879 and $525,463 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSIONS: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
PHP19 IMMUNIZATION PROGRAM IN PARAGUAY: SOCIAL AND BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL IMPACT
Maceira DA Center for the Study of the State and Society, Buenos Aires, Argentina OBJECTIVES: Public health care system in Paraguay is highly centralized, compared to other Latin American sectors, and more than half of the population relies on it in order to receive formal treatment. The National Immunization Program (EPI) is not an exemption, affecting the way local/departmental resources in immunization are allocated, impacting on the effectiveness of these investments. In addition, differences in population characteristics among departments, in terms of health care behavior, income and education, and the use of formal medicine patterns by original ethnic groups might affect EPIxs effectiveness. The goal of the paper is to identify how supply side characteristics (financial, managerial and immunization strategies) and demand side factors impact on immunization coverage. METHODS: The document proposes a sequential model, where local health authorities intent to fill the gap in immunization financing and managerial needs, based on the resources allocation and coverage strategy defined by the national health ministry, that leads the Paraguayan immunization design. As a result, a logistic model was implemented, where the likelihood of being vaccinated is tested as a dependent variable, where geographical, educational and ethnical barriers are checked. In addition, supply variables related to financing, coverage strategies and communicational efforts are included. The study analyze data from the Integrated National Household Survey (2001), complemented with a series of immunization effectiveness indexes constructed based on management, financing and vaccine provision criterion, distinguishing among financial sustainability, management effectiveness and antigen supply volatility, collected from official sources and interviews with key personnel by region. RESULTS: Health care policy variables were statistically significant, showing the relevance of social communication, measured in terms of physical, monetary and human resources involved. CONCLUSION: The paper shows the importance of socio-economic-cultural barriers on the probability of being immunized, based on health behavior, presence of formal health insurance, and main source of care (hospital, traditional medicine, etc.).
PHP20 THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE
Meerding WJ, Mackenbach J Erasmus MC, Rotterdam, The Netherlands OBJECTIVES: To assess the generic cost-effectiveness of health care. METHODS: We estimated the contribution of prevention and medical care towards population health for infectious diseases, cancers, and cardiovascular diseases. This contribution was defined as the difference between the current burden of disease (BoD) and its counterfactual: a 'null' situation without selected prevention (vaccinations, screening, and preventive medication) and medical care, and accounting for the role of other health determinants such as improvements in housing and nutrition, and reduced smoking. The counterfactual was backcalculated with use of historical data on incidence, survival, mortality, and the prevalence of risk factors. The Global Burden of Disease methodology was applied, combining incidence, prevalence, mortality, and disability weights into multi-state lifetables. If required, epidemiological estimates were made internally consistent with advanced modelling techniques (DISMOD2). The difference between the current BoD and the A366 Abstracts
